Abstract
Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably assess aspects of the molecular biology and neuropathology of AD. The aim of this article is to review the use of FDG-PET and amyloid PET imaging in the early detection of AD. Copyright © 2010 S. Karger AG, Basel.
Author supplied keywords
Cite
CITATION STYLE
Berti, V., Osorio, R. S., Mosconi, L., Li, Y., De Santi, S., & De Leon, M. J. (2010). Early detection of Alzheimer’s disease with PET imaging. In Neurodegenerative Diseases (Vol. 7, pp. 131–135). https://doi.org/10.1159/000289222
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
